US FDA approves higher dose of Novo Nordisk's hit weight-loss drug Wegovy
The approval comes as Novo Nordisk struggles to regain market share from competitors like Eli Lilly and faces price pressures due to Trump’s cost-cutting drive for drugs
The approval comes as Novo Nordisk struggles to regain market share from competitors like Eli Lilly and faces price pressures due to Trump’s cost-cutting drive for drugs
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
